Book a Meeting

BetterBet™ Anti-CD19 On-Target Antibody (CAT#: AES-0622-ZP704) Datasheet

Target
CD19
Description
Anti-CD19 antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
Applications
"On-target" tumor antigen binding
Technology
ATP-mediated antibody engineering technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19 molecule
Background
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Description
Anti-CD19 antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.

In the tumor microenvironment, ATP is released from necrotic, apoptotic and other tumor cells, so its concentration is higher than that of normal cells. On-Target Antibody takes advantage of the enrichment of ATP in the tumor microenvironment to activate the antibody with ATP as a medium, so that the antibody is specifically activated only in the tumor.

Related Products

Non-Fucosylated Anti-Human CD19 (MDX-1342) Therapeutic Antibody (CAT#: BioBet-645ZP)
Highly Galactosylated Anti-CD19 (Taplitumomab) Antibody (CAT#: BioBet-GA-100ZP)
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody (CAT#: BioBet-CB-030LX)
Non-fucosylated Anti-Human CD19 (Taplitumomab) Therapeutic Antibody (CAT#: BioBet-100ZP)
Non-Fucosylated Anti-Human CD19 (4G7) Therapeutic Antibody (CAT#: BioBet-1693ZP)
Non-Fucosylated Anti-Human CD19 (GBR 401) Therapeutic Antibody (CAT#: BioBet-1794ZP)
BetterBet™ Anti-CD19 Half-Life Extended Antibody (CAT#: AES-0622-ZP1032)
BetterBet™ Anti-CD19 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP376)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.